Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II clinical trial of ELE-Psilo+ for the adjunctive treatment of major depressive disorder

Next Previous
Trial Profile

Phase II clinical trial of ELE-Psilo+ for the adjunctive treatment of major depressive disorder

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Psilocybin (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use

Most Recent Events

  • 09 Nov 2022 According to a Beckley Psytech media release, the blinded data from the phase 1 trial in healthy volunteers will be used to help design this trial, with initiation planned for H1 2023.
  • 24 Oct 2022 According to a Beckley Psytech media release, the company aims to initiate a Phase 1 single ascending dose study before the end of 2022 and then subsequently will initiate this a proof-of-concept Phase 2a clinical study in patients with depression following soon after.
  • 12 Jul 2021 According to an Eleusis media release, the company expect to initiate this trial in early 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top